Scancell Holdings has received UK regulatory approval to conduct a phase III trial of its lead drug iSCIB1+ for advanced melanoma. The trial will enroll 550 patients across multiple countries, testing iSCIB1+ combined with two immunotherapy drugs against a placebo. The main goal is to measure progression-free survival to support accelerated approval, with overall survival as a secondary endpoint. The trial is expected to start by the end of 2026, with initial data due in late 2028. This follows prior FDA approval and ongoing applications in other regions, marking a key step toward potential marketing approval for the promising DNA-based treatment.
Kaito AI's new browser extension, Kaito Pulse, launched on August 18, has been scrutinized after an analyst's source-code review revealed it fingerprints devices and tracks detailed user activity on X, including posts viewed, clicks, searches, and bo...
Chainlink (LINK) has risen to $9.64, its highest since May 27, driven by a 15.1% weekly gain and strong whale accumulation with unique holders reaching a record 3.96 million. Despite trading 81.89% below its 2021 peak, analysts see LINK at a generati...
Hyperliquid's native token HYPE is trading around $59.37, showing strong technical support and bullish momentum. A major whale withdrew 57,000 tokens from Coinbase, signaling long-term accumulation, while derivatives trading surged nearly 19%. The Hy...
Smith & Nephew's share price fell about 3% after CFO John Rogers announced he will leave the company at the end of September 2026. Rogers has stepped down from the board immediately but will remain CFO until his departure. The company has appointed P...
Smith & Nephew's shares fell 3.5% after CFO John Rogers resigned from the board with immediate effect, officially leaving on September 30 to take a new position in the US. The company has started searching for his successor. Rogers had been with the ...
